Caspofungin: A new therapeutic option for fungal endocarditis [1]

Clinical Microbiology and Infection

Volumn 11, Issue 3, 2005, Pages 248-

  Nevado, Jaime ^a   De Alarcon A ^a   Hernandez A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CANDIDA GUILLIERMONDII; CASE REPORT; CLINICAL FEATURE; DRUG RESPONSE; ENDOCARDITIS; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; LETTER; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; PRIORITY JOURNAL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

CANDIDA; FUNGI; PICHIA GUILLIERMONDII;

EID: 14844363553     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01078.x     Document Type: Letter

References (6)

1. Garbino J. Caspofungin - a new therapeutic option for oropharyngeal candidiasis. Clin Microbiol Infect 2004; 10: 187-189.
2. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
3. Olaisson L, Petterson G. Current best practices and guidelines: indications for surgical intervention in infective endocarditis. Infect Dis Clin North Am 2002; 16: 453-475.
4. Pfaller MA, Jones RN, Doern GV et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44: 747-751.
5. Rex JH, Pfaller MA, Walsh TJ et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-658.
6. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.